NCT04849299

Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998)

A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Cyclosporine on the Plasma Pharmacokinetics of AT-527 in Healthy Adult Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study will determine the effect of cyclosporine on the PK of AT-527 (R07496998) in healthy male subjects

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	AT-527 550 mg + cyclosporine	550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
DRUG	AT-527 550 mg + cyclosporine	550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998

Timeline

• Start date: 2021-04-18
• Primary completion: 2021-05-10
• Completion: 2021-05-10
• First posted: 2021-04-19
• Last updated: 2021-08-02

Locations

1 site across 1 country: Canada